Results 201 to 210 of about 54,594 (319)

Supplementary Figure S9 from ATOR-4066, a Bispecific Antibody Targeting CD40 and CEACAM5, Induces Strong Myeloid and T Cell–Dependent Tumor Immunity and Synergizes with PD-1 Blockade

Hampus Andersson, Ida Uddbäck, Tova Hermodsson, Mona Celander, Amulya Krishna Shetty, Lill Ljung, Anneli Nilsson, Anette Sundstedt, Laura von Schantz, Laura A. Varas, Mattias Levin, Anna Säll, Dietmar Weilguny, K. Jansson, Sara Fritzell, Karin Hägerbrand, Malin Lindstedt, Peter Ellmark   +17 more
openalex   +1 more source

Building on bispecifics [PDF]

Nature Reviews Drug Discovery, 2019
openaire   +1 more source

Integrating MBMA and QSP to Identify Key Covariates and Predict Treatment Outcomes in Relapsed/Refractory Multiple Myeloma

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT This study demonstrates the application of a model based meta analysis (MBMA) framework to characterize the safety and efficacy profiles of therapies in relapsed and refractory multiple myeloma (RRMM). Published clinical trial data were analyzed to evaluate the incidence of Grade ≥ 3 neutropenia and overall response rate (ORR), providing a ...
Zeel Shah, Clifton M. Anderson, Kevin D. McCormick, Celeste Vallejo, William Duncan, Chuanpu Hu, Jian Zhou, Alexander V. Ratushny, Anna G. Kondic   +8 more
wiley   +1 more source

DNA-programmed bispecific peptide assemblies for delivering cytotoxic payload to cells expressing EGFR and MET receptors. [PDF]

RSC Chem Biol
Ghosh P, Dinh H, Seitz O.
europepmc   +1 more source

Next-generation T cell engagers in oncology: Pharmacologic evolution from bispecific to trispecific antibodies

Tarek Nahle, Viraj Shah, Sami Abi Farraj, Ali Atoui   +3 more
openalex   +2 more sources

Infectious Complications during Treatment with Commercial CAR T-Cell Therapy and Bispecific Antibodies for Relapsed/Refractory Multiple Myeloma [PDF]

Eric M. Jurgens, Tala Shekarkhand, Tasmin Farzana, Colin Rueda, David Nemirovsky, Andriy Derkach, Ross Firestone, Noriko Nishimura, Kevin Miller, Bruno Almeida Costa, Karthik Nath, Sridevi Rajeeve, Alexander M. Lesokhin, Neha Korde, Carlyn Tan, Hamza Hashmi, Hani Hassoun, Kylee Maclachlan, Urvi A. Shah, Malin Hultcrantz, Issam S. Hamadeh, Sergio Giralt, David J. Chung, Heather J. Landau, Michael Scordo, Gunjan L. Shah, Saad Z. Usmani, Sham Mailankody, Zainab Shahid   +28 more
openalex   +1 more source

A Generalized Minimal PBPK‐PD Model of Bispecific Antibodies: Case Studies and Applications in Drug Development

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Bispecific antibodies (bsAbs), for which each arm binds a distinct molecular target, are developed to engage soluble and cell surface targets in different therapeutic indications. Three key examples of mechanisms of action (MoA) for bsAbs are (1) immune cell engagers that foster immune cell interactions with target cells, (2) bispecifics that ...
Phillip Spinosa, Louis Joslyn, Saroja Ramanujan, Kapil Gadkar, Iraj Hosseini   +4 more
wiley   +1 more source

Anti-CD3 × Anti-Epidermal Growth Factor Receptor (EGFR) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers In vitro and in an Animal Model [PDF]

, 2006
Ursula Reusch, Magesh Sundaram, Pamela A. Davol, Sarah D. Olson, James B. Davis, Kurt Demel, Julie Nissim, Ritesh Rathore, Paul Y. Liu, Lawrence G. Lum   +9 more
openalex   +1 more source

China’s bispecific bet [PDF]

Nature Biotechnology, 2019
openaire   +1 more source

Targeting Overexpressed IDO in Stromal Cells as a Potential Therapeutic Strategy in Multiple Myeloma

Cancer Science, Volume 117, Issue 2, Page 325-334, February 2026.
IDO expression in stromal cells was upregulated by MM cells via the JAK–STAT1–NF‐κB–IRF1 signaling pathway. JAK inhibitor abolished IDO and IRF1 upregulation. ABSTRACT Stromal cells are an essential component of the tumor microenvironment (TME) in multiple myeloma (MM). Indoleamine 2,3‐dioxygenase 1 (IDO), an enzyme that metabolizes tryptophan (Trp) to
Toru Ebina, Masaki Ri, Yoshiaki Marumo, Tomoyuki Nakamura, Hirokazu Sasaki, Yoshiko Oshima, Takahiro Nakashima, Shinya Hagiwara, Arisa Asano, Shiori Kinoshita, Tomotaka Suzuki, Tomoko Narita, Ayako Masaki, Takaomi Sanda, Kazufumi Yamagata, Kohmei Kubo, Hirokazu Komatsu, Hirotake Sakuraba, Shinsuke Iida   +18 more
wiley   +1 more source